Orelabrutinib (ICP-022) is a potent, orally active, and irreversible Brutons tyrosine kinase (BTK) inhibitor with potential antineoplastic activity. Orelabrutinib prevents both the activation of the B-cell antigen receptor (BCR) signaling pathway and BTK-mediated activation of downstream survival pathways, inhibiting the growth of malignant B-cells that overexpress BTK[1][2].
Molecular Weight:
427.50
Purity:
99.97
CAS Number:
[1655504-04-3]
Formula:
C26H25N3O3
Target:
Btk
Application Notes:
MCE Product type: Reference compound1
* VAT and and shipping costs not included. Errors and price changes excepted